eScholarship
metadata only
Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy
Random conjugations of chemotherapeutics to monoclonal antibodies result in heterogeneous antibody-drug conjugates (ADCs) with suboptimal pharmacological properties. We recently developed a new technology for facile generation of homogeneous ADCs by harnessing human CD38 catalytic domain and its din
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.#452916
- Antibody-drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges.#152247
- The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates#273690
- Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.#122713
- From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates#922939
Record · ID 1065580
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive